Pfizer Inc. (BMV:PFE)
Mexico · Delayed Price · Currency is MXN | Market Cap | 2.74T -9.0% |
| Revenue (ttm) | 1.13T -1.6% |
| Net Income | 139.90B -3.2% |
| EPS | 24.56 -3.4% |
| Shares Out | n/a |
| PE Ratio | 19.61 |
| Forward PE | 9.08 |
| Dividend | 31.92 (6.61%) |
| Ex-Dividend Date | Jan 23, 2026 |
| Volume | 2,378 |
| Average Volume | 6,150 |
| Open | 490.00 |
| Previous Close | 490.00 |
| Day's Range | 480.00 - 491.40 |
| 52-Week Range | 427.00 - 532.12 |
| Beta | 0.41 |
| RSI | 56.49 |
| Earnings Date | Apr 28, 2026 |
About Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It als... [Read more]
Financial Performance
In 2025, Pfizer's revenue was $62.58 billion, a decrease of -1.65% compared to the previous year's $63.63 billion. Earnings were $7.77 billion, a decrease of -3.24%.
Financial numbers in USD Financial StatementsNews
Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial
Pharmaceutical giant Pfizer and French partner Valneva on Monday said they planned to seek regulatory approval for a Lyme disease vaccine after a late-stage trial.
Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial
Pharmaceutical giant Pfizer and French vaccine maker Valneva reported positive topline results from their phase three study of a vaccine candidate for Lyme disease.
Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial
U.S. drugmaker Pfizer and France's Valneva said on Monday their experimental Lyme disease vaccine showed more than 70% efficacy in a late-stage trial.
Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial
NEW YORK & LYON, France--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced topline results from the Phase 3 VALOR “Vaccine Against Lyme for Ou...
5 ‘Healthy' Dividends Paying Up To 14.1%
Healthcare dividend stocks are selling off with the turbulence in the Middle East.
Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that it has received notice of an unsolicited mini-tender offer by Tutanota LLC (“Tutanota”) to purchase up to 1 million shares of Pf...
TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhib...
TrumpRx lists many medicines at prices higher than paid in UK
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those ...
Pfizer: I'm Still Expecting A Massive Rebound
Pfizer Inc.'s non-COVID operational revenue grew 9% in Q4, successfully offsetting the ongoing decline in pandemic-related sales and signaling a structural shift toward long-term growth. The Seagen in...
Pfizer says experimental breast cancer drug cuts risk of disease worsening in mid-stage trial
Pfizer said on Tuesday its experimental combination reduced the risk of disease progression or death by 40% in patients with breast cancer.
Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the randomized Phase 2 FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versu...
Expect Pfizer To Comeback: Take The Dividend While Waiting For Capital Appreciation
Pfizer Inc. (PFE) is undervalued at 8–9× forward earnings, offering a nearly 7% dividend yield and significant upside potential. Recent acquisitions, especially Seagen, position PFE for robust growth,...
Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study
U.S. drugmaker Pfizer said on Monday its experimental drug for a chronic skin disease met the main goal in a mid-stage study.
Pfizer's Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from a Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate to severe atopic dermati...
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (March 2026)
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filter...
Wall Street Breakfast Podcast: India To Buy Russian Oil As War Disrupts Supplies
U.S. considers global AI chip export restrictions, impacting Nvidia and AMD as shares fall on regulatory risk. A 30-day U.S. waiver allows India to purchase stranded Russian crude, aiming to stabilize...
China approves Pfizer GLP-1 drug for weight management
China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight management in overweight or obese adults, the US drugmaker said on WeChat on Friday, boosting competition in a market ana...
Judge approves Pfizer, SEC settlement tied to insider trading at Cohen hedge fund
A federal judge on Thursday awarded Pfizer $29 million to resolve a dispute with the U.S. Securities and Exchange Commission stemming from the regulator's 2013 insider trading settlement with billio...
Seven S&P500 Ideal 'Safer' March Dividend Dogs
Seven S&P 500 dividend 'Dogs'—including VICI, VZ, BEN, F, HST, T, and KEY—offer high yields supported by sufficient free cash flow, making them attractive buys. Analyst forecasts project 14.2% to 32.2...
Pfizer's Portfolio Renewal In Progress - High Yields For The Patient
Pfizer's portfolio renewal is in progress, with new launches and acquisitions driving +14.6% YoY growth in new product revenues, though legacy drug expiries may pressure intermediate-term sales. These...
NYSE Content Update: Alysa Liu Rings NYSE Bell After Winning Two Gold Medals
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, March 4, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the N...
Pfizer's Quiet Cash Comeback
Pfizer delivers a 75.81% gross margin and 41.05% EBITDA margin, dramatically outperforming sector medians of 59.35% and 10.40%. Management targets $1.3 billion in net cost savings by 2026, reinforcing...
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Pfizer Inc. (PFE) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Pfizer Inc. (PFE) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Pfizer CEO flags issues with FDA's vaccine leadership
Pfizer CEO Albert Bourla on Monday flagged issues with the leadership of the U.S. Food and Drug Administration's vaccine department.